Novo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes
MarketWatch2022-03-29
Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.
Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added.
In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.
Novo Nordisk expects to launch Ozempic 2.0 milligram in the U.S. in the second quarter of 2022.
Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
